Ting Xu

Ting Xu

Chief Executive Officer at ALPHAMAB ONCOLOGY

Net worth: 367 M $ as of 31/05/2026

53 year
Health Technology
Consumer Services
Commercial Services

Profile

Founder of Alphamab Oncology and Suzhou Alphamab Co. Ltd., Ting Xu currently is Chairman, President & Chief Executive Officer at Suzhou Alphamab Co. Ltd., Director & General Manager at Jiangsu Alphamab Biopharmaceuticals Co. Ltd (a subsidiary of Suzhou Alphamab Co. Ltd.), Chairman & Chief Executive Officer for Alphamab Oncology and Chairman for Suzhou SmartNuclide Biopharmaceutical Co. Ltd. He is also on the board of Suzhou Bionovogene Biotech Co. Ltd., Shanghai Kangjing Bioscience Co. Ltd. and Suzhou Oncoimmune Co. Ltd. In the past Ting Xu occupied the position of Senior Scientist at Biogen Idec, Inc. (North Carolina). He received an undergraduate degree from the University of Nanjing and a doctorate and a graduate degree from Chinese Academy of Sciences.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
19/11/2025 315,675,016 ( 32.4% ) 367 M $ 31/05/2026

Ting Xu active positions

CompaniesPositionStart
ALPHAMAB ONCOLOGY Chief Executive Officer 01/10/2018
Founder 01/01/2008
Chief Executive Officer 01/01/2015
Founder 01/01/2015
Suzhou Bionovogene Biotech Co. Ltd.
Director/Board Member -
Shanghai Kangjing Bioscience Co. Ltd.
Director/Board Member -
Suzhou Oncoimmune Co. Ltd.
Director/Board Member -

Former positions of Ting Xu

CompaniesPositionEnd
Corporate Officer/Principal 01/01/2010
Chairman -
See the detail of Ting Xu's experience

Training of Ting Xu

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

97

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Consumer Services

Consumer Services

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Suzhou Bionovogene Biotech Co. Ltd.

Shanghai Kangjing Bioscience Co. Ltd.

Suzhou Oncoimmune Co. Ltd.

Commercial Services

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!